
Currently out of the existing stock ratings of Srikripa Devarakonda, 152 are a BUY (92.12%), 13 are a HOLD (7.88%).
Analyst Srikripa Devarakonda, currently employed at TRUIST, has had 62.18% of price targets met with an average potential upside of 43.04%, reached in 188 days on average.
Srikripa Devarakonda has documented 324 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MDGL, Madrigal Pharmaceuticals at 04-Nov-2026.
Analyst best performing recommendations are on NMTR.
The best stock recommendation documented was for NMTR on 6/30/2020. The price target of $400 was fulfilled within 1 day with a profit of $41 (11.42%), with a performance score of 114.21.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 03-May-2023
$117
$-3.97 (-3.28%)
$114
18 days ago
(30-Oct-2026)
52/59 (88.14%)
$-3.39 (-2.82%)
420
Hold Since 30-Oct-2026
$144
$23.03 (19.04%)
$107
18 days ago
(30-Oct-2026)
25/29 (86.21%)
$23.61 (19.61%)
655
Hold Since 20-Jan-2026
$127
$6.03 (4.98%)
$128
18 days ago
(30-Oct-2026)
13/16 (81.25%)
$6.61 (5.49%)
49
Buy Since 24-Nov-2025
$143
$22.03 (18.21%)
$139
18 days ago
(30-Oct-2026)
4/7 (57.14%)
$22.61 (18.78%)
153
Hold Since 03-Aug-2022
$127
$6.03 (4.98%)
$110
18 days ago
(30-Oct-2026)
3/4 (75%)
$6.61 (5.49%)
707
Which stock is Srikripa Devarakonda most bullish on?
Which stock is Srikripa Devarakonda most reserved on?
What Year was the first public recommendation made by Srikripa Devarakonda?